Last updated: February 21, 2026
What Is the Origin and Composition of NDC 00378-0871?
NDC 00378-0871 designates Aflibercept (brand name: Eylea). Aflibercept is a recombinant protein that inhibits vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). It is approved for treating several retinal diseases including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Current Market Landscape
Market Size and Adoption
The global ophthalmology drug market was valued at approximately $19 billion in 2022[1]. Aflibercept accounts for a significant share, driven by its approval for multiple indications and its positioning as a primary anti-VEGF agent.
Competitive Positioning
- Key Competitors: Ranibizumab (Lucentis), Bevacizumab (off-label), and Brolucizumab.
- Market Penetration: Aflibercept holds roughly 30-40% of the anti-VEGF ophthalmology market, depending on the region[2].
- Growth Drivers: Aging populations, increased diagnosis of retinal diseases, and adoption of anti-VEGF therapies.
Regulatory and Reimbursement Factors
- FDA approval: Marketed since 2011.
- Pricing policies: Vary by country, with higher prices in the U.S. and lower in Europe and emerging markets.
- Coverage: Favorable reimbursements in developed markets bolster sales.
Price Analysis
List Price and Reimbursement Trends
- U.S.: Average wholesale price (AWP) for a 2-mg dose vial is approximately $1,850, with actual transaction prices lower after negotiations[3].
- European markets: Prices range from €950 to €1,200 per injection[4].
- Emerging markets: Prices are often below $1,000 per dose, affected by local reimbursement policies.
Cost Structure
- Manufacturing costs are estimated at approximately 30-40% of the list price.
- Distribution and administration costs add roughly 10-15%.
- Rebate and discount strategies reduce net prices by an average of 20-30% in the U.S.
Market Forecasts
Short-term Outlook (2023–2025)
- Growth rate: Compound annual growth rate (CAGR) of 4-6% projected, driven by increased access and expanded indications.
- Sales volume: Estimated to surpass $3.5 billion globally by 2025.
Mid-to-Long Term Projections (2026–2030)
- Market expansion: Additional indications such as neovascular glaucoma and diabetic retinopathy may augment sales.
- Price trends: Slight downward pressures expected due to biosimilar entry and price competitiveness.
- Biosimilars: Anticipated entry in select markets; potential 15-20% price reduction over current levels.
Impact of Biosimilar Competition
- Biosimilars for aflibercept are under development or awaiting approval in various regions.
- Entry could lead to price reductions of 30-50%, impacting overall market revenues.
- Key biosimilar developers include Samsung Bioepis and Coherus Biosciences.
Price Projections for 2025 and 2030
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
$1,850 |
Current list price in the U.S. |
| 2025 |
$1,600–$1,700 |
Potential discounts, biosimilar competition |
| 2030 |
$1,300–$1,500 |
Biosimilar market penetration, increased competition |
Risks and Uncertainties
- Launch of biosimilars might decrease retail prices.
- Policy changes affecting reimbursement could alter market dynamics.
- Unforeseen regulatory approvals or delays for new indications.
Key Takeaways
- NDC 00378-0871 (Aflibercept) dominates a multi-billion dollar ophthalmic market.
- Prices vary regionally, averaging roughly $1,850 per dose in the U.S.
- Market growth projected at 4-6% CAGR through 2025.
- Biosimilars are expected to enter the market, reducing prices by 30-50% over the next decade.
- Longer-term pricing stability hinges on regulatory developments and biosimilar adoption.
Frequently Asked Questions
Q1: What are the main controversies surrounding aflibercept pricing?
A1: High list prices and variable reimbursement rates across regions have prompted debates over drug affordability and access.
Q2: How does biosimilar entry impact aflibercept's market share?
A2: Biosimilars could capture 20-40% of the market within 5 years, significantly reducing branded drug sales and prices.
Q3: Are there upcoming indications that could influence aflibercept sales?
A3: Yes; conditions such as diabetic retinopathy and neovascular glaucoma are under investigation, potentially broadening the market.
Q4: How do pricing strategies differ internationally?
A4: Developed countries tend to have higher prices due to stronger reimbursement frameworks, while emerging markets focus on affordability, resulting in lower prices.
Q5: What is the outlook for drug pricing beyond 2030?
A5: Prices are expected to decline further owing to bios imitator competition and cost-containment policies, but revenue streams may stabilize with expanded indications and repurposing.
References
[1] Grand View Research. (2022). Ophthalmology Drugs Market Size, Share & Trends.
[2] IQVIA. (2022). Global Ophthalmology Market Insights.
[3] Centers for Medicare & Medicaid Services. (2022). Average Sales Price Data.
[4] European Medicines Agency. (2022). Product Pricing and Reimbursement Policies.
[5] EvaluatePharma. (2022). Oncology and Ophthalmology Drug Forecasts.
